FGEN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FGEN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.
FibroGen's current Total Payout Ratio is 0.07.
The historical data trend for FibroGen's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FibroGen Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Total Payout Ratio | Get a 7-Day Free Trial | 0.27 | 0.20 | - | - | 0.17 |
FibroGen Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Total Payout Ratio | Get a 7-Day Free Trial | 0.40 | 0.20 | - | - | - |
For the Biotechnology subindustry, FibroGen's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, FibroGen's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where FibroGen's Total Payout Ratio falls into.
Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.
FibroGen's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Total Payout Ratio | = | - (Repurchase of Stock | + | Issuance of Stock | + | Cash Flow for Dividends) | / | Net Income |
= | - (0 | + | 48.407 | + | 0) | / | -284.232 | |
= | 0.17 |
FibroGen's Total Payout Ratio for the quarter that ended in Mar. 2024 is calculated as
Total Payout Ratio | = | - (Repurchase of Stock | + | Issuance of Stock | + | Cash Flow for Dividends) | / | Net Income |
= | - (0 | + | 0 | + | 0) | / | -32.933 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of FibroGen's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey William Henderson | director | 7000 CARDINAL PLACE, DUBLIN OH 43017 |
Enrique A Conterno | director, officer: Chief Executive Officer | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Thane Wettig | officer: Chief Commercial Officer | C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158 |
Christine Chung | officer: SVP, China Operations | C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158 |
Jeffrey L Edwards | director | 2525 DUPONT DR, IRVINE CA 92612 |
Aoife Brennan | director | 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139 |
Benjamin Cravatt | director | C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158 |
Suzanne Blaug | director | C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158 |
Maykin Ho | director | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
James A Schoeneck | director | C/O DEPOMED, INC., 1360 O'BRIEN DRIVE, MENLO PARK CA 94025 |
Mark Eisner | officer: Incoming Chief Medical Officer | C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158 |
Juan Graham | officer: Chief Financial Officer | C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158 |
Kearns Thomas F Jr | director | P O BOX 587, WARSAW IN 46581-0587 |
Pat Controneo | officer: VP, Finance and CFO | C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158 |
Kalevi Kurkijarvi | director | C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158 |
From GuruFocus
By sperokesalga sperokesalga • 02-17-2023
By Marketwired • 07-25-2023
By Marketwired • 07-01-2023
By sperokesalga sperokesalga • 06-07-2023
By sperokesalga sperokesalga • 04-24-2023
By Business Wire • 06-27-2023
By Marketwired • 07-24-2023
By Marketwired • 07-09-2023
By sperokesalga sperokesalga • 06-06-2023
By GuruFocus Research • 06-10-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.